Evidence map›Paper›PMID 41945921›Full record

ArticleChemSusChem2026

Highly Active CH Bond Borylation of Aromatics With Pyridine as Convenient, Low-Cost Ligand Under Iridium Catalysis.

Vanessa Delahaye, Thierry Roisnel, Sylvie Dérien, Mathieu Achard, Rafael Gramage-Doria

Abstract read
In one paragraph

Article in ChemSusChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Vanessa DelahayeUniv Rennes, CNRS, ISCR-UMR 6226, Rennes F-35000, France.ORCID https://orcid.org/0009-0003-6604-4719
Thierry RoisnelUniv Rennes, CNRS, ISCR-UMR 6226, Rennes F-35000, France.ORCID https://orcid.org/0000-0002-6088-4472
Sylvie DérienUniv Rennes, CNRS, ISCR-UMR 6226, Rennes F-35000, France.ORCID https://orcid.org/0000-0001-8439-0605
Mathieu AchardUniv Rennes, CNRS, ISCR-UMR 6226, Rennes F-35000, France.ORCID https://orcid.org/0000-0003-0578-9680
Rafael Gramage-DoriaUniv Rennes, CNRS, ISCR-UMR 6226, Rennes F-35000, France.ORCID https://orcid.org/0000-0002-0961-4530

Funding

CNRSUniversity of Rennes,Ministère del'Enseignement supérieur et de la Recherche
6 · The paper itself

Abstract

Although iridium-catalyzed CH bond borylation represents the archetypical example of step- and atom-economy transformation, the utilization of sophisticated and expensive ligands, which are typically prepared via extensive chemical manipulations raises questions about its overall sustainability in the synthetic arena. For instance, N,N-chelating ligands derived from 1,10-phenanthroline (phen) or 2,2'-bipyridine (bpy) scaffolds, whose synthesis relies on multistep transformations including the use of strong acids and oxidants, or costly palladium-catalyzed cross-coupling chemistry, respectively, dominate the field while affording high E-factor values and leading to an important carbon footprint. Herein we show that it is possible to replace these ligands by simple, unfunctionalized pyridine (pyr) ligand in the iridium-catalyzed CH bond borylation of aromatic substrates that feature CH bonds that are relatively acidic such as phthalimides and related 1,2-disubstituted aromatics. As a result, turnover numbers superior to 500 with catalyst loading as low as 0.1 mol% were disclosed for the CH bond borylation of compounds relevant for biology and materials sciences. In addition, the catalytic system was found to be compatible with 2-MeTHF as a green solvent.

Indexed as

borylationCH functionalizationgreen solventsiridiumpyridine

Identifiers

PMID41945921
PMCPMC13056381

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.